Genetics of Central Nervous System Arteriovenous Malformations (GENE-MAV)

Last updated: November 19, 2024
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hemangioma

Abnormal Blood Vessels (Arteriovenous Malformations)

Holoprosencephaly

Treatment

blood sample

Clinical Study ID

NCT04772963
SSA_2021_3
  • All Genders

Study Summary

Cerebral and medullary arteriovenous malformations (AVMs) lead to arterial and venous networks to communicate pathologically, creating an arteriovenous shunt. The occurrence of intracranial haemorrhage is the most important prognostic factor of AVMs because it is associated with a significant morbidity and mortality. The genetic, molecular and cellular mechanisms that cause vascular malformations of the central nervous system are partially known and the influence of genetic damage on the prognosis of AVMs is poorly known.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient with a vascular malformation of the cerebral or medullary identified ondiagnostic imaging (angio-CT, angio-MRI or diagnostic angiography) for whichclinical monitoring alone or intervention (endovascular treatment, surgery orradiosurgery) is planned in the centres participating in the research.

Exclusion

Exclusion Criteria:

  • Pregnant, parturient or breastfeeding woman

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: blood sample
Phase:
Study Start date:
February 17, 2022
Estimated Completion Date:
October 31, 2026

Study Description

Cerebral and medullary arteriovenous malformations (AVMs) are morphologically abnormal vessels located on the surface or in the cerebral or medullary parenchyma. These vascular lesions cause the arterial and venous networks to communicate pathologically, creating an arteriovenous shunt.

The prevalence of cerebral Cerebral and medullary AVMs in general population is difficult to establish given the rarity of the condition. However, it is estimated at around 1 per 10,000 inhabitants (0.01%). About 15-20% of the cerebral vascular accidents are asymptomatic at the time of diagnosis. The occurrence of intracranial haemorrhage is the most important prognostic factor because it is associated with a significant morbidity and mortality. The management of an AVM is usually carried out in a multidisciplinary way, combining interventional neuroradiology, neurosurgery and vascular neurology.

The genetic, molecular and cellular mechanisms that cause vascular malformations of the central nervous system are partially known. Several recent research works highlight mutations in the RAS-MAPK or MAPK-ERK signalling pathway in AVMs. In cases of cerebral AVMs considered to be sporadic, a somatic KRAS/BRAF mutation has recently been demonstrated in tissue samples of operated AVMs.

Except in the case of Hereditary Haemorrhagic Telangiectasia (HHT or Rendu-Osler-Weber syndrome), the influence of genetic damage on the prognosis of AVM is poorly known. It is also interesting to note that genetic screening is not routinely performed in patients with cerebro-medullary AVMs and that therefore the prevalence of these clinical entities in patients with AVMs is not known.

Connect with a study center

  • HOPITAL FONDATION Adolphe de ROTHSCHILD

    Paris, 75019
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.